Abeona Therapeutics, Inc.
(NASDAQ : ABEO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
-1.19%154.192.8%$391.70m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
-0.50%21.892.1%$239.33m
ZTSZoetis, Inc. Class A
-1.27%88.961.9%$228.28m
MYLMylan N.V.
-2.31%33.803.2%$207.41m
TXMDTherapeuticsMD, Inc.
0.42%4.7525.8%$17.27m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
3.83%36.602.0%$11.25m
ABEOAbeona Therapeutics, Inc.
-1.19%7.507.9%$5.24m
TAROTaro Pharmaceutical Industries Ltd.
-1.25%98.756.3%$4.56m
PETXAratana Therapeutics, Inc.
-2.93%6.308.7%$3.49m
KINKindred Biosciences, Inc.
-0.32%12.370.3%$2.18m
LFVNLifeVantage Corporation
2.28%11.663.3%$1.09m
CPHIChina Pharma Holdings, Inc.
-7.52%0.310.1%$0.36m
JAGXJaguar Animal Health, Inc.
-0.67%0.439.8%$0.25m

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX.